SCHEMBL633742

SCHEMBL633742

O=C(/C=C/c1ccccc1O)c1ccc(O)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 8/20 1.00
TYR P14679 1/20 0.79
BACE1 P56817 2/20 0.78
ABCG2 Q9UNQ0 1/20 0.76
BCHE P06276 1/20 0.73
GUSB P08236 1/20 0.73
NR1H4 Q96RI1 1/20 0.70
CYP3A4 P08684 3/20 0.69
MEN1 O00255 2/20 0.69
MAPT P10636 2/20 0.69
HPGD P15428 2/20 0.69
ALOX15 P16050 2/20 0.69
MAPK1 P28482 2/20 0.69
KMT2A Q03164 2/20 0.69
HSD17B10 Q99714 2/20 0.69
TDP1 Q9NUW8 2/20 0.69
KDM4E B2RXH2 1/20 0.69
ALDH1A1 P00352 1/20 0.69
THRB P10828 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29929576 1.00 CHRNA7 (1.00) CHRNA7TYRBACE1ABCG2BCHE
SCHEMBL322102 1.00 CHRNA7 (1.00) CHRNA7TYRBACE1ABCG2BCHE
SCHEMBL675095 0.88 TYR (1.00) CHRNA7TYRBACE1ABCG2CYP3A4
SCHEMBL675094 0.88 TYR (1.00) CHRNA7TYRBACE1ABCG2CYP3A4
SCHEMBL2977785 0.87 CHRNA7 (1.00) CHRNA7TYRBACE1BCHEGUSB
SCHEMBL2977786 0.87 CHRNA7 (1.00) CHRNA7TYRBACE1BCHEGUSB
SCHEMBL5426767 0.87 CHRNA7 (1.00) CHRNA7TYRBACE1BCHEGUSB
SCHEMBL5426768 0.87 CHRNA7 (1.00) CHRNA7TYRBACE1BCHEGUSB
SCHEMBL17975272 0.86 CHRNA7 (0.76) CHRNA7TYRBACE1ABCG2NR1H4
SCHEMBL130475 0.84 BCHE (1.00) CHRNA7BCHEGUSBCYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2986136-B1 COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING MARS INC (US) 2020-08-12 EP claimed
EP-2986136-A1 COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING The Iams Company (US) 2016-02-24 EP claimed
CN-105188400-A Compositions and methods for preventing, reducing, alleviating, or treating idiopathic vomiting IAMS COMPANY 2015-12-23 CN claimed
US-20140271949-A1 Composition and Method for Preventing, Reducing, Alleviating or Treating Idiopathic Vomiting THE IAMS COMPANY (US) 2014-09-18 US claimed
WO-2014143539-A1 COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING THE IAMS COMPANY (US) 2014-09-18 WO claimed
CN-118105365-A Use of a compound in the manufacture of a medicament for preventing or treating idiopathic vomiting in a companion animal 马斯公司 2024-05-31 CN disclosed
CN-105188400-B Compositions and methods for preventing, alleviating or treating idiopathic vomiting 马斯公司 2024-04-05 CN disclosed
US-11857657-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2024-01-02 US disclosed
EP-4228408-A1 PEST REPELLENTS AND USES THEREOF Sensorygen, Inc. (US) 2023-08-23 EP disclosed
WO-2023150072-A1 COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER SINCLAIR DAVID A (US) 2023-08-10 WO disclosed
CN-109134205-B Diarylalkanes as potent inhibitors of binuclear enzymes 尤尼根公司 2022-07-19 CN disclosed
WO-2022082106-A1 PEST REPELLENTS AND USES THEREOF Sensorygen, Inc. (US) 2022-04-21 WO disclosed
EP-1625150-B1 TRIPEPTIDES AND DERIVATIVES THEREOF FOR COSMETIC APPLICATION IN ORDER TO IMPROVE SKIN STRUCTURE PENTAPHARM AG (CH) 2007-01-03 EP disclosed
WO-2006127539-A1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2006-11-30 WO disclosed
US-20060270614-A1 Use of chalcones for the treatment of viral disorders JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2006-11-30 US disclosed
US-20060241094-A1 Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use CITY OF HOPE 2006-10-26 US disclosed
US-20060040876-A1 Modulation of peroxisome proliferator-activated receptors ABGENOMICS CORPORATION (TW) 2006-02-23 US disclosed
EP-1611887-A2 Modulation of peroxisome proliferator-activated receptors Abgenomics Corporation (TW) 2006-01-04 EP disclosed
WO-2005117849-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN PHARMACEUTICALS, INC. (US) 2005-12-15 WO disclosed
US-20050267047-A1 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN PHARMACEUTICALS, INC. (US) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267047-A1 Diarylalkanes as potent inhibitors of binuclear enzymes TYR, DDT, HAAO CHRNA7 2457/4885TYR 1/4885BACE1 1091/4885
US-20060270614-A1 Use of chalcones for the treatment of viral disorders HAVCR2, HMGB3, EIF2AK2 CHRNA7 4811/4885TYR 1529/4885BACE1 3952/4885
US-20060241094-A1 Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use ESR2, ESRRA, ESRRB CHRNA7 272/4885TYR 3300/4885BACE1 2724/4885
US-11857657-B2 Diarylalkanes as potent inhibitors of binuclear enzymes TYR, DDT, HAAO CHRNA7 2457/4885TYR 1/4885BACE1 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.